Agile Therapeutics
AGRX
AGRX was delisted on the 25th of March, 2024.
36 hedge funds and large institutions have $182M invested in Agile Therapeutics in 2022 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 11 increasing their positions, 8 reducing their positions, and 11 closing their positions.
892% more capital invested
Capital invested by funds: $18.4M → $182M (+$164M)
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
38% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 8
20% less funds holding
Funds holding: 45 → 36 (-9)
64% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 11
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$1.45M |
| 2 |
Renaissance Technologies
New York
|
+$147K |
| 3 |
FCBT
First Citizens Bank & Trust
Raleigh,
North Carolina
|
+$63.8K |
| 4 |
PFM
Parsec Financial Management
Asheville,
North Carolina
|
+$22.3K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$17.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$358K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$197K |
| 3 |
NIM
Needham Investment Management
New York
|
-$171K |
| 4 |
VF
Virtu Financial
New York
|
-$116K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$46K |
AGRX Hedge Fund Activity: Q1 2022 in Review
36 of the 6,341 institutional investors tracked by Wall St. Rank reported a position in Agile Therapeutics (AGRX) for Q1 2022, worth a combined $182M — up 892% from $18.4M a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of AGRX and 4 opened new positions — a net loss of 7 holders — while 8 trimmed existing stakes and 11 added.
The largest buyer was Armistice Capital, opening a new position worth an estimated $1.45M. The largest seller was GSA Capital Partners, exiting entirely with an estimated $358K sold.
- 36 institutional investors held Agile Therapeutics (AGRX) as of Q1 2022, down from 45 in Q4 2021.
- Funds reported $182M of Agile Therapeutics stock for Q1 2022, up 892% quarter-over-quarter.
- 4 funds opened new Agile Therapeutics positions in Q1 2022 and 11 closed out, a net change of -7 holders.
- The largest Agile Therapeutics buyer in Q1 2022 was Armistice Capital, an estimated $1.45M added.
- The largest Agile Therapeutics seller in Q1 2022 was GSA Capital Partners, an estimated $358K sold.
Based on aggregated 13F filings for Q1 2022.